Rebuild Cells, Rescue Lives

Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics) was established in 2019. It is a biotechnology company dedicated to the innovation and development of novel cell therapies and drugs for the treatment of solid tumors. We focus on developing safer, more effective, more accessible and more affordable immune cell therapies that are not constrained by any fixed molecular targets and are designed to address both the most prevalent and the most refractory solid tumors. 

Leveraging our proprietary DeepTIL™ cell enrichment expansion platform, NovaGMP™ non-viral gene-modification platform and RiverTIL™ in vivo TIL platform, we have established a strong technological foundation for continuously developing a pipeline of first-in-class and best-in-class natural and gene-modified TIL therapies. 

GC101, is the world's first TIL therapy that does not require high-intensity lymphodepletion chemotherapy or the use of IL-2 administration, has brought long-term benefits to patients with advanced metastatic solid tumors who failed multiple lines of treatment, including melanoma, non-small cell lung cancer, cervical cancer, endometrial cancer, pancreatic cancer and glioma. Multiple patients have achieved complete tumor clearance, with the longest tumor-free survival exceeding four years.